The NISCI study is closed.
No patients will be included anymore.
For questions please contact the NISCI team via firstname.lastname@example.org.
NISCI study - More than 110 patients enrolled and the study is on its final stretch for successful completion of the trial in 2022.
The NISCI biobank, first of its kind in Europe for patients suffering from acute SCI, is starting in collaboration with the Uni Bochum to analyse bio samples to understand recovery profile.
38 Mio € for Spinal Cord Injury Research by Wings for Life World Run on Mai 8 2022. Wings for Life supports cutting edge international research.
NISCI is one of the supported projects.
The next Wings for Life World Run will take place on May 7 2023, more here https://www.wingsforlifeworldrun.com/en
ISCOS 2021 goes virtual! The 60th International Spinal Cord Society Annual Scientific Meeting takes place online from 29 September to 2 October 2021.
PD Dr. Mirko Aach ist Kongress-Präsident der DMGP 2021
NISCI (Nogo-A Inhibition in acute Spinal Cord Injury) is a multicenter, multinational, placebo controlled phase-II study for the safety and preliminary efficacy of intrathecal anti-Nogo-A [NG101] in patients with acute cervical spinal cord injury. The purpose of the NISCI trial is to test if an antibody therapy can improve motor function and quality of life of tetraplegic patients.
Until now 50 patients have been included in the trial. The study has been extended by the Horizon2020 program until 2022.
Find more about the trial and eligibility criteria on our website.
In case of any specific question please contact a participating study center.
NISCI study @ German TV
Interview with Prof. N. Weidner, Heidelberg (D)
9 May 2021 a unique Wings for Life run starts worldwide at the same time https://www.wingsforlifeworldrun.com/en
A new trial finder online - find a spinal cord injury clinical trial that interests you under https://scitrialsfinder.net/home.
Given the current public health concerns - it has been unfortunately decided to cancel all Runs planned for 3 May.
More >> here
Anti Nogo-A im Rahmen der NISCI Studie.
Eiweiße hemmen, damit Nerven sich erholen.
more >> https://www.zeit.de/wissen/gesundheit/2019-09/querschnittlaehmung-heilung-behandlung-nervensystem-hoffnung-rollstuhl
THERAPIE-STUDIE ZU AKUTER QUERSCHNITTLÄHMUNG GEHT IN DIE ZWEITE PHASE
Heidelberger Studienleiter Prof. Dr. Norbert Weidner im Gespräch
news room Klinikum uni Heidelberg, 12.09.2019
Martin Schwab has achieved what many researchers dream of their entire lives. Due to his discovery, science now understands why injured nerves within the spinal cord don’t re-grow.
Entire interview >> here